Aspirin Global Market Report 2026

Aspirin is a nonsteroidal anti-inflammatory drug used to relieve fever and mild pain. Its chemical name is acetylsalicylic acid (ASA). It is commonly used to treat conditions such as arthritis and to lower the risk of events such as heart attacks and strokes.

The main categories of aspirin products include prescription and over-the-counter (OTC) formulations. Prescription drugs require authorization from a licensed physician. Based on the route of administration, aspirin is segmented into oral, rectal, and parenteral forms. Available dosage forms include tablets, capsules, injections, and suppositories. Aspirin is utilized for various applications, including cardiovascular diseases, pain, fever, inflammation, and others, and is used by end users such as hospitals, clinics, and other healthcare settings.

Tariffs have affected the aspirin market by increasing the cost of imported raw materials and pharmaceutical intermediates, leading to higher production costs for manufacturers. The prescription and OTC segments are most impacted, especially in regions like North America and Europe that rely on imports. While tariffs have created pricing pressures, they also encourage local manufacturing investments and innovation in cost-efficient production, which could strengthen domestic market capabilities over time.

The aspirin market research report is one of a series of new reports from The Business Research Company that provides aspirin market statistics, including aspirin industry global market size, regional shares, competitors with a aspirin market share, detailed aspirin market segments, market trends and opportunities, and any further data you may need to thrive in the aspirin industry. This aspirin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The aspirin market size has grown strongly in recent years. It will grow from $2.66 billion in 2025 to $2.8 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to growing awareness of cardiovascular health, rising incidence of arthritis, increasing over-the-counter medicine adoption, advancements in pain and fever management, availability of low-cost aspirin products.

The aspirin market size is expected to see strong growth in the next few years. It will grow to $3.51 billion in 2030 at a compound annual growth rate (CAGR) of 5.8%. The growth in the forecast period can be attributed to development of targeted aspirin therapies, adoption of advanced manufacturing technologies, increasing preventive healthcare initiatives, growing focus on cardiovascular disease prevention, expansion of global distribution channels. Major trends in the forecast period include personalized dosage formulations, expansion of otc aspirin availability, rising cardiovascular disease awareness, advanced drug delivery systems, increasing geriatric population usage.

The substantial global burden of cardiovascular diseases is expected to drive the growth of the aspirin market in the coming years. Cardiovascular diseases encompass a range of conditions that affect the heart and blood vessels. Aspirin is commonly recommended as a preventive therapy for cardiovascular diseases, particularly among individuals at risk of heart attacks or strokes. For example, in May 2024, according to the Singapore Heart Foundation (SHF), a Singapore-based non-profit organization, ischemic heart disease accounted for 5,302 deaths, reflecting a slight increase from 5,290 deaths in 2022. Therefore, the high prevalence of cardiovascular diseases worldwide is contributing to the expansion of the aspirin market.

Major companies operating in the aspirin market are adopting strategic partnership approaches to strengthen technology integration and expand their market presence. A strategic partnership generally refers to a collaborative arrangement between two or more organizations in which they combine resources, expertise, and capabilities to achieve shared objectives. For example, in February 2023, Huma Therapeutics Limited, a UK-based digital health company, partnered with Bayer AG, a Germany-based life sciences company, to launch the Bayer Aspirin Heart Risk Assessment online tool. This tool helps users identify their risk factors for developing cardiovascular disease over the next ten years and enables them to share the results with their healthcare provider. Huma developed an algorithm that estimates long-term cardiovascular disease risk using data from the UK Biobank. Users can access the Heart Risk Assessment tool through Bayer Aspirin, where they complete a user-friendly questionnaire consisting of 15 questions. Based on their responses, the tool determines whether individuals are at higher, average, or lower risk of developing cardiovascular disease by comparing their answers with data from the research population.

In May 2024, Sun Pharmaceutical Industries Ltd., an India-based specialty generic pharmaceutical company, acquired Taro Pharmaceutical Industries Ltd. for an undisclosed amount. Through this acquisition, Sun Pharma aims to strengthen its presence in the pharmaceutical market, particularly in segments such as off-patent medicines, prescription drugs, and over-the-counter products. Taro Pharmaceutical Industries Ltd. is an Israel-based research-driven pharmaceutical manufacturer that produces acetylsalicylic acid capsules.

Major companies operating in the aspirin market are Bayer AG, Allegiant Health, Par Pharmaceutical, Cardinal Health Inc., Nanjing pharmaceutical factory Co. Ltd., JQC (Huayin) Pharmaceutical Co. Ltd., LNK International Inc., Bal Pharma Limited, Trumac Healthcare, Perrigo Company PLC, Alta Laboratories Ltd., Zhenjiang Gaopeng Pharmaceutical Co. Ltd., J.M. Loveridge Ltd., Mayne Pharma Group Limited, St. Joseph's Aspirin, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Hetero Labs Ltd., Jubilant Generics Ltd., Lupin Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd.

Asia-Pacific was the largest region in the aspirin market in 2025. The regions covered in the aspirin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the aspirin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The aspirin market consists of sales of capsules, chewable, and coated tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Aspirin Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses aspirin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for aspirin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The aspirin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Prescription Aspirin; OTC (Over-the-Counter) Aspirin
• 2) By Route Of Administration: Oral; Rectal; Parenteral
• 3) By Dosage Form: Tablets; Capsules; Injections; Suppositories
• 4) By Application: Cardiovascular Disease; Pain; Fever; O Inflammation; Other Applications
• 5) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Prescription Aspirin: Low-Dose Aspirin (81 Mg); High-Dose Aspirin (325 Mg)
• 2) By OTC (Over-the-Counter) Aspirin: Regular Strength Aspirin (325 Mg); Extra-Strength Aspirin (500 Mg); Buffered Aspirin; Aspirin Combinations
• Companies Mentioned: Bayer AG; Allegiant Health; Par Pharmaceutical; Cardinal Health Inc.; Nanjing pharmaceutical factory Co. Ltd.; JQC (Huayin) Pharmaceutical Co. Ltd.; LNK International Inc.; Bal Pharma Limited; Trumac Healthcare; Perrigo Company PLC; Alta Laboratories Ltd.; Zhenjiang Gaopeng Pharmaceutical Co. Ltd.; J.M. Loveridge Ltd.; Mayne Pharma Group Limited; St. Joseph's Aspirin; Teva Pharmaceutical Industries Ltd; Boehringer Ingelheim International GmbH; Cadila Healthcare Ltd.; Cipla Ltd.; Dr. Reddy's Laboratories Ltd.; GlaxoSmithKline plc; Hetero Labs Ltd.; Jubilant Generics Ltd.; Lupin Ltd.; Merck & Co. Inc.; Novartis AG; Pfizer Inc.; Sanofi S.A.; Sun Pharmaceutical Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.